Neos Therapeutics Files For IPO

Grand Prarie, Texas-based Neos Therapeutics, which is developing biopharmaceuticals aimed at treating ADHD, has filed for an IPO, saying that it plans to raise $69.0M on an IPO. The company has applied to list on the NASDAQ Global Market as NEOS. The IPO is being underwritten by UBS Investment Bank, BMO Capital Markets, RBC Capital Markets, and JMP Securities. NEOS is led by Vipin Garg, and venture backed by Burrill Life Sciences Capital Fund, Delaware Street Capital, Presidio Partners, Essex Capital, CAC, John Patient Trust, and Deerfield Private Design, among others.